Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Gulf Pharmaceutical Industries PSC ROE % Related Terms
Gulf Pharmaceutical Industries PSC ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Gulf Pharmaceutical Industries PSC's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gulf Pharmaceutical Industries PSC ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Gulf Pharmaceutical Industries PSC's ROE % distribution charts can be found below:
* The bar in red indicates where Gulf Pharmaceutical Industries PSC's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a ROE % of 14.54% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. This is 2070% above median its historical median of 0.67. According to the industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #60 out of 113 companies in the Medical Distribution industry, placing it in the top 53.1%.
Is Gulf Pharmaceutical Industries PSC's ROE % too high?
Gulf Pharmaceutical Industries PSC's current ROE % of 14.54% is 2070% above median its 10-year median of 0.67. The Medical Distribution industry median ROE % is 7.15. Gulf Pharmaceutical Industries PSC's value of 14.54% is 103.4% above this industry median. Based on the distribution chart, Gulf Pharmaceutical Industries PSC ranks #60 out of 113 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's ROE % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Gulf Pharmaceutical Industries PSC ranks #60 out of 113 companies for ROE %. This places Gulf Pharmaceutical Industries PSC in the lower half of its industry. The industry median ROE % is 7.15. Gulf Pharmaceutical Industries PSC's value of 14.54% is 103.4% above this benchmark. While the company's 10-year median is 0.67 vs. the industry median of 7.15, Gulf Pharmaceutical Industries PSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.15, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gulf Pharmaceutical Industries PSC's current ROE % of 14.54% is 103.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. For the Medical Distribution industry, the median ROE % is 7.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gulf Pharmaceutical Industries PSC's current ROE % is 14.54%, which is 2070% above median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.09, compared to a current price of د.إ1.04 — trading 4.6% below its estimated fair value. The current ROE % is 14.54%, which is 2070% above median its 10-year median of 0.67 and 103.4% above the Medical Distribution industry median of 7.15. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current ROE % is 14.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued.
The current stock price of د.إ1.04 is trading 4.6% below its estimated GF Value™ of د.إ1.09.
GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.
Key valuation signals for ADX:JULPHAR:
ROE %: 14.54% (2070% above median its 10-year median of 0.67)
GF Value™: د.إ1.09 vs. price of د.إ1.04 (4.6% below fair value)
Industry Position: 103.4% above the Medical Distribution median (#60 of 113)
No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gulf Pharmaceutical Industries PSC Business Description
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
54GF Score
Get the complete analysis for ADX:JULPHAR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADX:JULPHAR has been successfully added to your 
